Researchers have mapped a previously unseen drug-binding pocket on PKMYT1, a kinase tied to cancer cell division, using X-ray crystallography to show that the site locks the protein into an inactive shape. The finding, published in the Journal of the American Chemical Society, offers a route to blocking tumor-driving signals without competing at the standard ATP-binding groove where most kinase inhibitors crowd in and hit off-target proteins. Parallel discoveries of hidden pockets on two other cancer-relevant proteins, cereblon and KRAS, reinforce a broader shift: experimental screening methods are exposing druggable surfaces that computational prediction alone has missed.
Why a Hidden Pocket on PKMYT1 Changes the Drug-Design Calculus
Most kinase-targeted cancer drugs work by wedging into the ATP-binding cleft, the engine room where the enzyme transfers phosphate groups to downstream proteins. The problem is that roughly five hundred human kinases share a structurally similar ATP pocket, so a drug designed for one kinase often inhibits others, producing side effects that narrow the margin between a therapeutic dose and a toxic one. The PKMYT1 finding sidesteps that constraint. By binding at an allosteric site, away from the conserved ATP groove, a small molecule can induce a unique inactive conformation of the kinase without relying on the shared architecture that makes selectivity so difficult.
The practical prediction that follows is straightforward: allosteric ligands stabilizing this newly mapped inactive state should display a wider therapeutic index than ATP-site inhibitors because they avoid the conserved residues responsible for cross-kinase activity. Testing that prediction would require head-to-head kinome-wide selectivity panels and rodent toxicity comparisons, neither of which has been reported yet. Still, the structural data published so far provide the first concrete template for designing such compounds against PKMYT1.
Another advantage of this allosteric strategy is its potential to complement, rather than replace, ATP-competitive inhibitors. In principle, a low-dose ATP-site drug could be combined with an allosteric PKMYT1 inhibitor that stabilizes the inactive conformation, lowering the exposure needed for each agent and potentially easing toxicity. That combinatorial logic will only be testable once medicinal chemists have produced compounds with adequate solubility, metabolic stability, and oral bioavailability-properties that the current crystallographic ligands were not optimized to achieve.
Crystallography, Tethering Screens, and the Pattern Across Three Proteins
The PKMYT1 pocket was resolved through X-ray crystallography, a method that freezes protein–ligand complexes in crystal form and maps atomic positions with angstrom-level resolution. That level of detail revealed not just where the allosteric ligand sits but how its binding reshapes the ATP site into a conformation incompatible with catalytic activity. The structural evidence was paired with biochemical and cell-based assays confirming that the conformational shift translates into measurable kinase inhibition.
Two independent studies on different cancer targets echo the same theme. A team reporting in Nature identified an allosteric site on cereblon, the E3 ligase adapter protein central to a growing class of blood-cancer therapies called targeted protein degraders. Their work showed that a compound designated SB-40548 binds cereblon at this allosteric pocket, opening a potential control point for tuning degrader activity. Separately, researchers used cysteine mutagenesis and disulfide tethering screens to identify cryptic pockets on oncogenic KRAS mutants, a family of proteins long considered nearly impossible to drug. Together, these three studies demonstrate that hidden binding surfaces are not rare curiosities; they appear repeatedly when scientists apply experimental screening strategies rather than relying solely on computational models of known protein structures.
The cereblon discovery carries additional weight because targeted protein degraders built around cereblon are already in clinical use or late-stage trials for multiple myeloma and other cancers. A review in Nature Reviews Drug Discovery cataloged safety concerns with cereblon-recruiting degraders, distinguishing on-target toxicity from off-target protein destruction. An allosteric handle on cereblon could, in principle, let chemists fine-tune degrader selectivity and reduce unwanted collateral damage, though no clinical data on that strategy exist yet.
For KRAS, the tethering screens illustrate how chemical biology can turn a “smooth” protein surface into a patchwork of actionable cavities. By engineering cysteine residues and screening small disulfide fragments, the researchers forced transient grooves to reveal themselves as they formed covalent links. The resulting map of cryptic pockets does not immediately yield a drug, but it does offer a prioritized list of surface regions where medicinal chemists can focus noncovalent optimization campaigns.
Gaps Between Structural Proof and Patient-Ready Drugs
The distance between a crystal structure and a medicine remains large. For PKMYT1, the published evidence stays at the biochemical and cellular level. No patient-derived xenograft models or clinical safety datasets for allosteric PKMYT1 compounds have been reported. Without animal efficacy and toxicity numbers, the selectivity advantage predicted by the structural data is still a hypothesis, not a validated therapeutic property.
A similar gap exists for the cereblon allosteric ligand SB-40548. While the structural and binding data are clear, no trial sponsor filings or regulatory submissions tied to cereblon allosteric modulators have surfaced publicly. The safety framing available comes from mechanistic reviews rather than direct clinical observation. For KRAS, the disulfide tethering screens produced druggability assessments of the newly found cryptic pockets, but those assessments lack matched in vivo efficacy data from the same study cohort, making it hard to judge which pockets will hold up in living systems.
What connects all three cases is a recurring bottleneck: experimental methods can now find hidden pockets faster than drug developers can validate them in animals and patients. The next concrete milestone to watch is the progression from structural ligands-molecules designed primarily to bind and reveal a pocket-to bona fide lead compounds with demonstrated activity in disease-relevant models. That transition typically demands iterative cycles of medicinal chemistry, pharmacokinetic profiling, and functional testing that extend well beyond the scope of initial structural reports.
What Comes Next for Hidden Allosteric Sites
For PKMYT1, the logical next step is to translate the allosteric scaffold into tool compounds suitable for in vivo use. Such molecules would need sufficient potency, selectivity, and exposure to test whether locking PKMYT1 in its inactive state slows tumor growth without triggering the dose-limiting toxicities seen with broader kinase inhibitors. Parallel work could explore whether combining an allosteric PKMYT1 inhibitor with DNA-damaging chemotherapy or cell-cycle checkpoint blockers yields synergistic effects in preclinical models.
In the cereblon field, the newly defined allosteric pocket invites experiments that modulate degrader behavior indirectly. Rather than altering the degrader molecule itself, researchers could add an allosteric cereblon ligand to dial up or down the rate at which specific substrates are tagged for destruction. If successful, this approach might offer a way to rescue efficacy in tumors that have adapted to existing degraders, or to mitigate side effects by temporarily dampening cereblon activity in vulnerable tissues.
For KRAS, the path is more exploratory. The cryptic pockets uncovered by tethering provide footholds for fragment-based drug discovery campaigns that may eventually yield noncovalent inhibitors of mutant KRAS variants beyond those already targeted clinically. Even if only a subset of these pockets prove druggable in vivo, each new site expands the menu of strategies for tackling one of oncology’s most stubborn drivers.
Taken together, the PKMYT1, cereblon, and KRAS studies mark a subtle but important pivot in small-molecule discovery. Instead of accepting the visible grooves of a static protein structure as the full landscape, researchers are treating proteins as dynamic objects whose hidden states can be trapped, visualized, and ultimately exploited. Whether this shift will translate into safer, more selective cancer therapies remains to be seen, but the structural blueprints now on the table give drug designers more options than they had even a few years ago-and raise the prospect that many more “undruggable” targets may simply be waiting for their own cryptic pockets to be found.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
